🚀 Exciting Collaboration Announcement! 🚀
April 28, 2025
We at
Pharmidex have been delighted to collaborate closely with the talented teams at
Apeikon Therapeutics and
King's College London to generate exciting new data in the field of oncology research.
We are proud to share that our collaborative poster will be presented this afternoon at the AACR Annual Meeting 2025 in Chicago! 🇺🇸✨
📄 Check out the poster and learn more here:
https://lnkd.in/e7-TVBB9
A huge thank you to everyone involved for making this project a success, we are looking forward to continuing to push the boundaries of discovery together!
If you're attending AACR, come and visit, we would love to discuss our findings and explore new opportunities for collaboration.
#Pharmidex #AACR2025 #Collaboration #OncologyResearch #DrugDiscovery #TranslationalResearch #Teamwork #Innovation
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.
